Avedro (maker of the FDA approved corneal cross-linking system) announced more results from their phase 3 clinical trial for the treatment of corneal ectasia following refractive surgery.
The summary?
At the 12 month follow up, they found:
- Steep K values decreased by 0.7D while controls continued to steepen by 0.6D.
- Visual acuity improved by 5 letters.
- Corneal haze was the most frequent adverse event.
To refresh you, Avedro received FDA approval for corneal cross-linking for both keratoconus (approved April 2016) and corneal ectasia following refractive surgery (approved July 2016). So far, the one year results for both have been positive.
Here are the one year results for the keratoconus trial (Glance summary here) and the details of how exactly the cross-linking procedure is done (Glance summary here).
